RE:RE:RE:RE:RE:Not surprisingGlad to see you seem to have more information than me, because part of what you say about better selecting cancer types and patients in better shape was not part of their PR yesterday. So some people sold today without knowing that if true, and still, personally I need to believe your info is true. I am not saying you are inventing it. I just say that I am down to believing somebody on Stockhouse, even if I know he is a big shareholder.
Who told you that? Again, nothing personal, but it would have been much better to hear it from the company. Why are they leaking stuff to some well placed people, and not to the small investor like me? And even if the info would have been directly from them, their credibility level is as low as it can be in my view. Their track record is awful.
SPCEO1 wrote: You said "And now with lower and more frequent dosing, they will aim more at stable diseases than clear objective responses that would allow a fast approval."
Based on what I have heard the company said, this is not what THTX is thnking. It seems they got some mild responses and are looking to tweek the dosing approach and the targeted cancers as wel as the relative health of the patients to get a better response rate. They do not seem very interested in stabilizing the patient's cancer but rather are aiming for a significant impact. So, they are altering the dosing in such a way as to actually get moreTH-1902 into the body than previously by using more frequent dosing of smaller amounts, they are targeting a narrower range of cancers where they believe the hit rate will be more in their favor and are seeking somewhat healthier patients than have taken the drug so far. It sounds like they have learned a thing or two about which patients may not respond well based on previous therapies they have taken and will seek to avoid those.
My impression is they will be putting the new protocol together with the assistance of the trial investigators so hopefully that helps with recruitment once they start up again as the investigators will have been part of the solution. Apparently, another peptide drug conjugate company did similiar alterations to their trial and got better results.